Interferon alpha-2b controlled release - Biolex/OctoPlus

Drug Profile

Interferon alpha-2b controlled release - Biolex/OctoPlus

Alternative Names: BLX 883 controlled release - Biolex/OctoPlus; Locteron

Latest Information Update: 16 Apr 2013

Price : $50

At a glance

  • Originator Biolex
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Hepatitis C

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
  • 03 Jul 2012 Biolex files for Chapter 7 bankruptcy in the US Bankruptcy Court for the Middle District of North Carolina
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top